What is Ophirex?
Ophirex is at the forefront of developing innovative treatments for severe medical needs, particularly focusing on snakebite envenoming and other conditions stemming from bites and stings. The company's commitment extends to diseases and injuries with related biological mechanisms, aiming to provide affordable and accessible oral treatment options. As a public benefit corporation, Ophirex prioritizes societal impact alongside its scientific and commercial objectives, positioning itself as a key player in neglected tropical diseases and emergency medicine.
How much funding has Ophirex raised?
Ophirex has raised a total of $37M across 1 funding round:
Series B
$37M
Series B (2023): $37M with participation from AXA IM Prime Impact Master Fund
Key Investors in Ophirex
AXA IM Prime Impact Master Fund
AXA IM Prime Impact Master Fund is an investor focused on impact-driven opportunities, likely aligning with Ophirex's mission to address critical global health needs through accessible medical treatments.
What's next for Ophirex?
The recent major strategic investment signifies a pivotal moment for Ophirex, likely enabling the acceleration of its research and development pipeline, clinical trials, and market penetration strategies. This capital infusion is expected to bolster the company's efforts to bring its groundbreaking oral treatment for snakebite envenoming to a global scale. The focus on 'strategic investment' suggests a partnership aimed at leveraging expertise and resources to overcome regulatory hurdles and ensure widespread availability of its life-saving therapies, particularly in regions most affected by these critical health issues.
See full Ophirex company page
